A newly approved blood test for Alzheimer’s disease, developed with contributions from Indiana University researchers, marks a major step forward in how the disease can be diagnosed. By detecting specific biomarkers in blood, this test offers a simpler, less invasive, and more widely accessible alternative to traditional diagnostic tools like PET scans and spinal fluid analysis.
Image Credit: AtlasStudio/Shutterstock.com
Until now, confirming Alzheimer’s typically required imaging techniques such as PET scans or analyzing cerebrospinal fluid through lumbar punctures—methods that, while accurate, are invasive, expensive, and not easily scalable. This new blood test changes that. It targets disease-related proteins in the bloodstream, offering a practical solution for earlier and broader detection.
How Alzheimer’s Progresses—and How We’ve Diagnosed it
Alzheimer’s disease is driven by the buildup of amyloid plaques and tau tangles in the brain, which cause gradual neurodegeneration. Historically, diagnosis has relied on observing clinical symptoms and confirming them with PET imaging or spinal fluid tests that measure these biomarkers.
However, as research into Alzheimer’s deepened, scientists began looking for less invasive ways to detect the same biological changes. Blood-based biomarkers—specifically phosphorylated tau (pTau) and beta-amyloid (Aβ)—emerged as key indicators. But measuring them accurately in blood required major advances in biosensor technology.
Inside the Technology
The heart of the new test is a biosensor system capable of detecting extremely low levels of pTau and Aβ in blood. It uses immunoassays, where molecules like antibodies or aptamers selectively bind to the target proteins. These binding events trigger signals, either electrical or optical, that correspond to the amount of biomarker present.
To ensure precision, the researchers optimized every element of the sensor: the recognition molecules, signal amplification techniques, and even the surface chemistry. They validated the system in diverse patient populations, comparing results against the gold-standard PET and spinal fluid tests to confirm reliability.
What the Results Show
The assay specifically measures pTau217 and Aβ1-42—two key proteins tied to Alzheimer’s pathology. pTau217 is particularly important, as it strongly correlates with both amyloid buildup and tau tangle formation. The test uses ultra-sensitive platforms like Simoa (Single Molecule Array) to detect these proteins at extremely low levels.
In clinical studies, the test achieved over 90 % accuracy in identifying Alzheimer’s-related changes, matching the performance of more invasive methods. It also uses the ratio of pTau217 to Aβ to improve diagnostic precision, reducing the risk of false positives or negatives.
Validation followed rigorous protocols, including large-scale studies and statistical analyses like ROC curves to confirm high sensitivity and specificity. The process adhered to CLIA standards, ensuring the test is accurate and repeatable in real-world clinical settings.
What This Means for Patients and Providers
This FDA-approved test represents a meaningful leap in Alzheimer’s diagnostics. It’s fast, minimally invasive, and scalable, making it suitable for routine use in primary care or memory clinics. The ability to detect early signs of disease could lead to earlier interventions, more effective clinical trial recruitment, and improved patient care.
Looking ahead, researchers are working to integrate this biosensor into more user-friendly devices, with the goal of making Alzheimer’s screening part of standard health assessments.